Fingolimod (Gilenya) licence extension recommended

A committee of the European Medicines Agency (EMA) has recommended the extension to the licensing of fingolimod (Gilenya) that would mean people can be prescribed the drug if they continue to have relapses despite treatment with at least one disease modifying therapy (previous this only applied after beta interferon treatment) . EMA Reuters Fingolimod (Gilenya) - A to Z of MS
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news